|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM338270809 |
| 003 |
DE-627 |
| 005 |
20231226000309.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.108980
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1127.xml
|
| 035 |
|
|
|a (DE-627)NLM338270809
|
| 035 |
|
|
|a (NLM)35296428
|
| 035 |
|
|
|a (PII)S1521-6616(22)00061-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Hoang, Trang T T
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Measurement of anti-suprabasin antibodies, multiple cytokines and chemokines as potential predictive biomarkers for neuropsychiatric systemic lupus erythematosus
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.04.2022
|
| 500 |
|
|
|a Date Revised 20.05.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Neuropsychiatric systemic lupus erythematosus (NPSLE) varies in presentation and is one of the leading causes of morbidity and mortality among patients with SLE. This study determined the most critical serum biomarkers for the development of NPSLE as they may have clinical utility prior to the onset of neuropsychiatric symptoms. We retrospectively analyzed 35 NPSLE patients, 34 SLE patients, 20 viral meningitis (VM) patients, and 16 relapsing-remitting multiple sclerosis (MS) patients. We measured anti-suprabasin antibodies concentrations in serum by using Luciferase immunoprecipitation system (LIPS) assay. The serum concentrations of cytokines/chemokines were measured by using multiplex bead-based assay. We found serum FGF-2 level was significantly higher in the NPSLE group compared to the SLE group and the healthy control group. The anti-suprabasin antibody relative concentration (SRC) has high positive predictive values for the development of NPSLE. The most essential biomarkers are VEGF, anti-suprabasin antibodies, sCD40L, IL-10, GRO, MDC, IL-8, IL-9, TNF-α, MIP-1α
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Bayesian posterior predictive values
|
| 650 |
|
4 |
|a Chemokines
|
| 650 |
|
4 |
|a Cytokines
|
| 650 |
|
4 |
|a NPSLE
|
| 650 |
|
4 |
|a SOIL
|
| 650 |
|
4 |
|a Suprabasin
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a Chemokines
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 700 |
1 |
|
|a Ichinose, Kunihiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Morimoto, Shimpei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Furukawa, Kaori
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Le, Ly H T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kawakami, Atsushi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 237(2022) vom: 10. Apr., Seite 108980
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:237
|g year:2022
|g day:10
|g month:04
|g pages:108980
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.108980
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 237
|j 2022
|b 10
|c 04
|h 108980
|